This Technical Paper is brought to you by Gnosis by Lesaffre.
Bactolife has designed binding protein ingredients to neutralize harmful gut metabolites and pathogens without disrupting beneficial microbes in the gut. Liz Spence, the company’s US general manager, and Sandra Wingaard Thrane, its CSO and co-founder, explain how these proteins mimic passive immunity, support gut barrier function, and help maintain microbiome balance. They share findings from preclinical and animal studies, upcoming human trials, and progress toward US and EU authorization. The company anticipates launching its first products in the US in 2026.
Settings
- Play Interval
- Slide Duration
- Thumbnail Bar Position
Latest headlines

Brought to you by:
Cabio

Beauty-from-within Dec 2025
Multimedia
Bactolife has designed binding protein ingredients to neutralize harmful gut metabolites and pathogens without disrupting beneficial microbes in the gut. Liz Spence, the company’s US general manager, and Sandra Wingaard Thrane, its CSO and co-founder, explain how these proteins mimic passive...





























